ArticleBMC immunology2025
Association between antivimentin/cardiolipin antibodies and pregnancy loss in pregnant women with at least one spontaneous miscarriage.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionAntivimentin/cardiolipin antibodies (aVim/CL) have emerged as potential diagnostic markers for antiphospholipid syndrome, However, their association with pregnancy outcomes remains unclear. This study explores the clinical significance of aVim/CL in pregnancy loss.
methodsA retrospective analysis was conducted on 429 pregnant women with at least one spontaneous miscarriage at The Third Affiliated Hospital of Wenzhou Medical University (October 2019- August 2022). Multivariable logistic regression and stratified analyses were utilized to assess the relationship between aVim/CL levels and pregnancy loss.
resultsAmong the 429 participants, 79 experienced pregnancy loss, while 350 had live births. Elevated aVim/CL levels were associated with an increased risk of pregnancy loss, with an odds ratio (OR) of 1.108 (95% CI, 1.037-1.185). The area under the ROC curve (AUC) was 62.8, with a sensitivity of 77.2% and a specificity of 44%. A nonlinear L-shaped relationship was identified, with a threshold of 6.86 ng/mL, below which the risk of pregnancy loss significantly increased. No correlations were found between aVim/CL and coagulation or immune biomarkers. DISCUSSION: Elevated aVim/CL levels were identified as independent predictors of pregnancy loss in women with a history of spontaneous miscarriage. The threshold of 6.86 ng/mL may provide valuable clinical insights for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.